# OnCo record ret-fusion (biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/biomarkers/ret-fusion/>
  a schema:MedicalTest ;
  onco:kind "biomarker" ;
  schema:identifier "ret-fusion" ;
  schema:name "RET fusion and RET mutation"@en ;
  schema:alternateName "RET fusion"@en, "RET rearrangement"@en, "RET fusion-positive"@en, "KIF5B-RET"@en, "KIF5B::RET"@en, "CCDC6-RET"@en, "RET mutation"@en, "RET M918T"@en, "RET-mutant medullary thyroid cancer"@en, "RET-altered"@en ;
  schema:description "RET fusions drive 1 to 2 percent of lung cancers and some thyroid cancers; RET point mutations drive medullary thyroid cancer. Selpercatinib is approved for RET fusions in any solid tumour and for RET-mutant medullary thyroid cancer; pralsetinib for RET fusion lung cancer."@en ;
  schema:url <https://onco.cc/biomarkers/ret-fusion/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7fa848ba-a59c-4144-9f52-64d090f4d828>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16edd46e-28b8-f06d-e063-6394a90ae31b> ;
  onco:tag "biomarker", "fusion" ;
  onco:related <https://onco.cc/biomarkers/alk-fusion/>, <https://onco.cc/biomarkers/ntrk-fusion/>, <https://onco.cc/biomarkers/ros1-fusion/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/thyroid/>, <https://onco.cc/cancers/medullary-thyroid-cancer/>, <https://onco.cc/cancers/papillary-thyroid-cancer/>, <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:drugs <https://onco.cc/drugs/selpercatinib/>, <https://onco.cc/drugs/pralsetinib/>, <https://onco.cc/drugs/oncomine-dx-target-test/>, <https://onco.cc/drugs/foundationone-cdx/>, <https://onco.cc/drugs/trusight-oncology-comprehensive/> ;
  onco:terms <https://onco.cc/terms/gene-fusion/>, <https://onco.cc/terms/tumour-agnostic/>, <https://onco.cc/terms/tki-term/> .